On the public citation graph

68 Ga-Labeled Inhibitors of Prostate-Specific Membrane Antigen (PSMA) for Imaging Prostate Cancer

0 signed · 239 inferred · view as graph

Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.

Is this your work? Sign in with ORCID and put your name on the claims that are yours.
Claim with ORCID
Reference health. See whether every reference in this work resolves to a known work and none has been retracted — and get a dated CiteStamped badge you can embed.
See reference health

What this work says

Outgoing claims: the papers this work cites, builds on, or argues with.

inferredcites →https://doi.org/10.1002/(sici)1521-3765(19990503)5:5<1503::aid-chem1503>3.0.co;2-6openalex-snapshot
Single- or Dual-Mode Switching of Semisynthetic Ribonuclease S′ with an Iminodiacetic Acid Moiety in Response to the Copper(II) Concentration
inferredcites →https://doi.org/10.1002/(sici)1521-3765(19990702)5:7<1974::aid-chem1974>3.0.co;2-xopenalex-snapshot
Radiometal-Labelled Macrocyclic Chelator-Derivatised Somatostatin Analogue with Superb Tumour-Targeting Properties and Potential for Receptor-Mediated Internal Radiotherapy
inferredcites →https://doi.org/10.1002/chem.200701264openalex-snapshot
Metal‐Ion‐Dependent Biological Properties of a Chelator‐Derived Somatostatin Analogue for Tumour Targeting
inferredcites →https://doi.org/10.1002/cmmi.232openalex-snapshot
68 Ga‐PET: a powerful generator‐based alternative to cyclotron‐based PET radiopharmaceuticals
inferredcites →https://doi.org/10.1002/cne.903150208openalex-snapshot
Immunocytochemical localization of the N‐acetyl‐aspartyl‐glutamate (NAAG) hydrolyzing enzyme N‐acetylated α‐linked acidic dipeptidase (NAALADase)
inferredcites →https://doi.org/10.1002/jcb.10661openalex-snapshot
Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer
inferredcites →https://doi.org/10.1007/s00259-003-1330-yopenalex-snapshot
Positron flight in human tissues and its influence on PET image spatial resolution
inferredcites →https://doi.org/10.1007/s00259-003-1436-2openalex-snapshot
Exceptional increase in somatostatin receptor expression in pancreatic neuroendocrine tumour, visualised with 68 Ga-DOTATOC PET
inferredcites →https://doi.org/10.1007/s00259-009-1205-yopenalex-snapshot
Detection of unknown primary neuroendocrine tumours (CUP-NET) using 68Ga-DOTA-NOC receptor PET/CT
inferredcites →https://doi.org/10.1007/s00726-010-0515-5openalex-snapshot
A cell permeable peptide analog as a potential-specific PET imaging probe for prostate cancer detection
inferredcites →https://doi.org/10.1016/0003-2697(70)90146-6openalex-snapshot
Color test for detection of free terminal amino groups in the solid-phase synthesis of peptides
inferredcites →https://doi.org/10.1016/j.ejmech.2009.10.038openalex-snapshot
Anticancer activity of dinuclear gallium(III) carboxylate complexes
inferredcites →https://doi.org/10.1016/j.ejso.2009.01.007openalex-snapshot
Clinical indications for Gallium-68 positron emission tomography imaging
inferredcites →https://doi.org/10.1016/j.poly.2006.06.039openalex-snapshot
Synthesis, structure and thermal analysis of the gallium complex of 1,4,7,10-tetraazacyclo-dodecane-N,N′,N″,N‴-tetraacetic acid (DOTA)
inferredcites →https://doi.org/10.1016/s0020-1693(00)80229-7openalex-snapshot
Stabilities of trivalent metal ion complexes of the tetraacetate derivatives of 12-, 13- and 14-membered tetraazamacrocycles
inferredcites →https://doi.org/10.1016/s0020-1693(97)06091-xopenalex-snapshot
An electrospray mass spectrometric investigation of gallium trihalide and indium trihalide solutions
inferredcites →https://doi.org/10.1021/bc0601673openalex-snapshot
Influence of Different Spacers on the Biological Profile of a DOTA−Somatostatin Analogue
inferredcites →https://doi.org/10.1021/jm0306226openalex-snapshot
Synthesis of Urea-Based Inhibitors as Active Site Probes of Glutamate Carboxypeptidase II: Efficacy as Analgesic Agents
inferredcites →https://doi.org/10.1021/jm0612618openalex-snapshot
Gallium(III) and Iron(III) Complexes of α-N-Heterocyclic Thiosemicarbazones: Synthesis, Characterization, Cytotoxicity, and Interaction with Ribonucleotide Reductase
inferredcites →https://doi.org/10.1021/jm800111uopenalex-snapshot
Synthesis and Evaluation of Technetium-99m- and Rhenium-Labeled Inhibitors of the Prostate-Specific Membrane Antigen (PSMA)
inferredcites →https://doi.org/10.1021/jm800765eopenalex-snapshot
Interactions between Human Glutamate Carboxypeptidase II and Urea-Based Inhibitors: Structural Characterization
inferredcites →https://doi.org/10.1021/jm801055hopenalex-snapshot
Radiohalogenated Prostate-Specific Membrane Antigen (PSMA)-Based Ureas as Imaging Agents for Prostate Cancer
inferredcites →https://doi.org/10.1021/jm900528dopenalex-snapshot
Impact of Metal Coordination on Cytotoxicity of 3-Aminopyridine-2-carboxaldehyde Thiosemicarbazone (Triapine) and Novel Insights into Terminal Dimethylation
inferredcites →https://doi.org/10.1021/jm950801qopenalex-snapshot
Design, Synthesis, and Biological Activity of a Potent Inhibitor of the Neuropeptidase N-Acetylated α-Linked Acidic Dipeptidase
inferredcites →https://doi.org/10.1021/mp900069dopenalex-snapshot
Prostate-Specific Membrane Antigen Targeted Imaging and Therapy of Prostate Cancer Using a PSMA Inhibitor as a Homing Ligand
inferredcites →https://doi.org/10.1021/mp9000712openalex-snapshot
Design, Synthesis, and Preclinical Evaluation of Prostate-Specific Membrane Antigen Targeted 99mTc-Radioimaging Agents
inferredcites →https://doi.org/10.1158/1078-0432.ccr-04-2690openalex-snapshot
Radiolabeled Small-Molecule Ligands for Prostate-Specific Membrane Antigen:In vivoImaging in Experimental Models of Prostate Cancer
inferredcites →https://doi.org/10.1158/1078-0432.ccr-07-1517openalex-snapshot
N-[N-[(S)-1,3-Dicarboxypropyl]Carbamoyl]-4-[18F]Fluorobenzyl- l -Cysteine, [18F]DCFBC: A New Imaging Probe for Prostate Cancer
inferredcites →https://doi.org/10.1200/jco.2006.07.8097openalex-snapshot
Vascular Targeted Therapy With Anti–Prostate-Specific Membrane Antigen Monoclonal Antibody J591 in Advanced Solid Tumors
inferredcites →https://doi.org/10.2967/jnumed.106.038091openalex-snapshot
68Ga-Labeled Bombesin Studies in Patients with Gastrointestinal Stromal Tumors: Comparison with 18F-FDG
inferredcites →https://doi.org/10.2967/jnumed.107.040378openalex-snapshot
Processing of Generator-Produced 68Ga for Medical Application
inferredcites →https://doi.org/10.2967/jnumed.108.053041openalex-snapshot
Peptide-Based Probes for Cancer Imaging
inferredcites →https://doi.org/10.2967/jnumed.109.066589openalex-snapshot
Assessment of an 18F-Labeled Phosphoramidate Peptidomimetic as a New Prostate-Specific Membrane Antigen–Targeted Imaging Agent for Prostate Cancer
inferredcites →https://doi.org/10.2967/jnumed.109.068957openalex-snapshot
Salvage Therapy with 177Lu-Octreotate in Patients with Bronchial and Gastroenteropancreatic Neuroendocrine Tumors
inferredcites →https://doi.org/10.4103/0019-509x.62998openalex-snapshot
Non-FDG PET in the practice of oncology
inferredcites →https://doi.org/10.4161/cbt.7.6.5968openalex-snapshot
Characterization of a targeted nanoparticle functionalized with a urea-based inhibitor of prostate-specific membrane antigen (PSMA)

What points at this work

Incoming claims: where this work appears in other papers’ reference lists and arguments.

inferred← citeshttps://doi.org/10.2139/ssrn.4996194openalex-extracted
Synthesis and Study of Hynic Conjugated Psma Targeting Ligands for Prostate Cancer Diagnosis
inferred← citeshttps://doi.org/10.1002/9781118833322.ch19openalex-snapshot
Receptor‐Mediated Drug Delivery
inferred← citeshttps://doi.org/10.1002/9781119300229.ch12openalex-snapshot
Chemical Probes Targeting Proteases for Imaging and Diagnostics in Cancer
inferred← citeshttps://doi.org/10.1002/9783527827855.ch11openalex-snapshot
Metal Complexes as the Means or the End of Targeted Delivery for Unmet Needs
inferred← citeshttps://doi.org/10.1002/ajoc.201900329openalex-snapshot
Prostate‐Specific Membrane Antigen (PSMA)‐Targeted Radionuclide Probes for Imaging and Therapy of Prostate Cancer
inferred← citeshttps://doi.org/10.1002/ange.201102872openalex-snapshot
Sequential SPECT and Optical Imaging of Experimental Models of Prostate Cancer with a Dual Modality Inhibitor of the Prostate‐Specific Membrane Antigen
inferred← citeshttps://doi.org/10.1002/ange.201503417openalex-snapshot
Synthesis and Evaluation of GdIII‐Based Magnetic Resonance Contrast Agents for Molecular Imaging of Prostate‐Specific Membrane Antigen
inferred← citeshttps://doi.org/10.1002/anie.201102872openalex-snapshot
Sequential SPECT and Optical Imaging of Experimental Models of Prostate Cancer with a Dual Modality Inhibitor of the Prostate‐Specific Membrane Antigen
inferred← citeshttps://doi.org/10.1002/anie.201503417openalex-snapshot
Synthesis and Evaluation of GdIII‐Based Magnetic Resonance Contrast Agents for Molecular Imaging of Prostate‐Specific Membrane Antigen
inferred← citeshttps://doi.org/10.1002/cbic.201400001openalex-snapshot
A New Bifunctional Chelator Enables Facile Biocoupling and Radiolabeling as the Basis for a Bioconjugation Kit
inferred← citeshttps://doi.org/10.1002/cnr2.1169openalex-snapshot
Comparison of prostate‐specific membrane antigen ligands in clinical translation research for diagnosis of prostate cancer
inferred← citeshttps://doi.org/10.1002/jlcr.2990openalex-snapshot
Rapid, one‐step, high yielding 18F‐labeling of an aryltrifluoroborate bioconjugate by isotope exchange at very high specific activity
inferred← citeshttps://doi.org/10.1002/jlcr.3255openalex-snapshot
Synthesis and in vivo evaluation of gallium‐68‐labeled glycine and hippurate conjugates for positron emission tomography renography
inferred← citeshttps://doi.org/10.1002/jlcr.3414openalex-snapshot
Prospects of medium specific activity 177 Lu in targeted therapy of prostate cancer using 177 Lu‐labeled PSMA inhibitor
inferred← citeshttps://doi.org/10.1002/med.21508openalex-snapshot
Targeting prostate cancer: Prostate‐specific membrane antigen based diagnosis and therapy
inferred← citeshttps://doi.org/10.1002/pros.21413openalex-snapshot
Imaging prostate cancer lymph node metastases with a multimodality contrast agent
inferred← citeshttps://doi.org/10.1002/pros.22789openalex-snapshot
Improving the biodistribution of PSMA-targeting tracers with a highly negatively charged linker
inferred← citeshttps://doi.org/10.1007/978-1-4939-1176-9_4openalex-snapshot
New Imaging Modalities
inferred← citeshttps://doi.org/10.1007/978-3-030-42618-7_20openalex-snapshot
Non-FDG PET/CT
inferred← citeshttps://doi.org/10.1007/978-3-319-64096-9_27openalex-snapshot
Molecular Imaging of Prostate Cancer: Radiopharmaceuticals for Positron Emission Tomography (PET) and Single-Photon Emission Computed Tomography (SPECT)
inferred← citeshttps://doi.org/10.1007/978-3-319-68517-5_19openalex-snapshot
PET/MRI in Prostate Cancer
inferred← citeshttps://doi.org/10.1007/978-3-319-93339-9_1openalex-snapshot
New Imaging Techniques in Prostate Cancer
inferred← citeshttps://doi.org/10.1007/978-3-662-50468-0_2openalex-snapshot
Physikalisch-technische Grundlagen und Tracerentwicklung in der Positronenemissionstomografie
inferred← citeshttps://doi.org/10.1007/s00259-013-2527-3openalex-snapshot
Preclinical evaluation of BAY 1075553, a novel 18F-labelled inhibitor of prostate-specific membrane antigen for PET imaging of prostate cancer
inferred← citeshttps://doi.org/10.1007/s00259-016-3578-zopenalex-snapshot
Early dynamic imaging in 68Ga- PSMA-11 PET/CT allows discrimination of urinary bladder activity and prostate cancer lesions
inferred← citeshttps://doi.org/10.1007/s00259-017-3631-6openalex-snapshot
68Ga-PSMA-11 PET/CT in primary staging of prostate cancer: PSA and Gleason score predict the intensity of tracer accumulation in the primary tumour
inferred← citeshttps://doi.org/10.1007/s00259-017-3670-zopenalex-snapshot
68Ga-PSMA PET/CT: Joint EANM and SNMMI procedure guideline for prostate cancer imaging: version 1.0
inferred← citeshttps://doi.org/10.1007/s00259-018-3970-yopenalex-snapshot
Optimal time-point for 68Ga-PSMA-11 PET/CT imaging in assessment of prostate cancer: feasibility of sterile cold-kit tracer preparation?
inferred← citeshttps://doi.org/10.1007/s00259-020-05169-zopenalex-snapshot
[18F]-JK-PSMA-7 and [18F]-FDG tumour PET uptake in treated xenograft human prostate cancer model in mice
inferred← citeshttps://doi.org/10.1007/s00259-022-05931-5openalex-snapshot
The maximum standardized uptake value in patients with recurrent or persistent prostate cancer after radical prostatectomy and PSMA-PET-guided salvage radiotherapy—a multicenter retrospective analysis
inferred← citeshttps://doi.org/10.1007/s00259-022-06089-wopenalex-snapshot
PSMA PET/CT: joint EANM procedure guideline/SNMMI procedure standard for prostate cancer imaging 2.0
inferred← citeshttps://doi.org/10.1007/s00761-017-0246-2openalex-snapshot
Theranostik
inferred← citeshttps://doi.org/10.1007/s10354-017-0569-zopenalex-snapshot
68Ga-PSMA-11 PET/CT: the rising star of nuclear medicine in prostate cancer imaging?
inferred← citeshttps://doi.org/10.1007/s11307-014-0800-xopenalex-snapshot
BAY 1075553 PET-CT for Staging and Restaging Prostate Cancer Patients: Comparison with [18F] Fluorocholine PET-CT (Phase I Study)
inferred← citeshttps://doi.org/10.1007/s11307-015-0850-8openalex-snapshot
Initial Evaluation of [18F]DCFPyL for Prostate-Specific Membrane Antigen (PSMA)-Targeted PET Imaging of Prostate Cancer
inferred← citeshttps://doi.org/10.1007/s11307-017-1091-9openalex-snapshot
Repeatability of [68Ga]DKFZ11-PSMA PET Scans for Detecting Prostate-specific Membrane Antigen-positive Prostate Cancer
inferred← citeshttps://doi.org/10.1007/s11307-018-1207-xopenalex-snapshot
Evaluating Ga-68 Peptide Conjugates for Targeting VPAC Receptors: Stability and Pharmacokinetics
inferred← citeshttps://doi.org/10.1007/s11934-013-0389-7openalex-snapshot
Lymphotropic Nanoparticle-enhanced MRI in Prostate Cancer: Value and Therapeutic Potential
inferred← citeshttps://doi.org/10.1007/s13233-013-1050-5openalex-snapshot
Synthesis and biological evaluation of substrate-based imaging agents for the prostate-specific membrane antigen
inferred← citeshttps://doi.org/10.1007/s41365-016-0134-2openalex-snapshot
Preparation and biodistribution assessment of 68Ga-DKFZ-PSMA-617 for PET prostate cancer imaging
inferred← citeshttps://doi.org/10.1007/s41972-023-00204-1openalex-snapshot
Falsch-positive – falsch-negative Befunde – Stellenwert der PSMA-PET/CT beim Staging von Patienten mit Prostatakarzinom
inferred← citeshttps://doi.org/10.1007/s44174-024-00235-8openalex-snapshot
Nanoparticles for Cancer Gene Therapy and Imaging
inferred← citeshttps://doi.org/10.1016/b978-0-12-407722-5.00017-7openalex-snapshot
Radionuclides for Imaging and Therapy in Oncology
inferred← citeshttps://doi.org/10.1016/b978-0-443-22253-5.00026-1openalex-snapshot
Radionuclides for imaging and therapy in oncology
inferred← citeshttps://doi.org/10.1016/j.actbio.2022.12.017openalex-snapshot
NIR-II-triggered photothermal therapy with Au@PDA/PEG-PI for targeted downregulation of PSMA in prostate cancer
inferred← citeshttps://doi.org/10.1016/j.addr.2010.09.007openalex-snapshot
Radiopharmaceutical chemistry for positron emission tomography
inferred← citeshttps://doi.org/10.1016/j.apradiso.2012.10.014openalex-snapshot
The untapped potential of Gallium 68-PET: The next wave of 68Ga-agents
inferred← citeshttps://doi.org/10.1016/j.apradiso.2013.01.039openalex-snapshot
Clinical applications of Gallium-68
inferred← citeshttps://doi.org/10.1016/j.apradiso.2021.109692openalex-snapshot
Simple new method for labelling of PSMA-11 with 68Ga in NaHCO3
inferred← citeshttps://doi.org/10.1016/j.apradiso.2025.111893openalex-snapshot
Synthesis and biological evaluation of a 68Ga-labeled glucose derivative PET probe [68Ga]Ga-NOTA-SDG
inferred← citeshttps://doi.org/10.1016/j.biomaterials.2010.10.034openalex-snapshot
A multimodal nanoparticle-based cancer imaging probe simultaneously targeting nucleolin, integrin αvβ3 and tenascin-C proteins
inferred← citeshttps://doi.org/10.1016/j.biomaterials.2015.11.048openalex-snapshot
PSMA-specific theranostic nanoplex for combination of TRAIL gene and 5-FC prodrug therapy of prostate cancer
inferred← citeshttps://doi.org/10.1016/j.bioorg.2019.103154openalex-snapshot
Tyrosine-based asymmetric urea ligand for prostate carcinoma: Tuning biological efficacy through in silico studies
inferred← citeshttps://doi.org/10.1016/j.bioorg.2025.108130openalex-snapshot
Design, synthesis, and biological evaluation of novel thiourea derivatives as small molecule inhibitors for prostate specific membrane antigen
inferred← citeshttps://doi.org/10.1016/j.bmc.2018.04.014openalex-snapshot
Development of a Ga-68 labeled PET tracer with short linker for prostate-specific membrane antigen (PSMA) targeting
inferred← citeshttps://doi.org/10.1016/j.bmcl.2012.09.014openalex-snapshot
Synthesis and SAR of 99mTc/Re-labeled small molecule prostate specific membrane antigen inhibitors with novel polar chelates
inferred← citeshttps://doi.org/10.1016/j.bmcl.2014.03.066openalex-snapshot
Structural characterization of P1′-diversified urea-based inhibitors of glutamate carboxypeptidase II
inferred← citeshttps://doi.org/10.1016/j.bmcl.2015.09.062openalex-snapshot
Carborane-containing urea-based inhibitors of glutamate carboxypeptidase II: Synthesis and structural characterization
inferred← citeshttps://doi.org/10.1016/j.ccr.2018.12.005openalex-snapshot
Radiotheranostics with radiolanthanides: Design, development strategies, and medical applications
inferred← citeshttps://doi.org/10.1016/j.cpet.2016.12.004openalex-snapshot
Gallium-68 Prostate-Specific Membrane Antigen PET Imaging
inferred← citeshttps://doi.org/10.1016/j.cpet.2022.07.003openalex-snapshot
18F-Labeled Radiotracers for Prostate-specific Membrane Antigen
inferred← citeshttps://doi.org/10.1016/j.ejmcr.2021.100014openalex-snapshot
Total chemical synthesis of PSMA-11: API for 68Ga-PSMA-11 used for prostate cancer diagnosis
inferred← citeshttps://doi.org/10.1016/j.ejmcr.2022.100084openalex-snapshot
A convenient total synthesis of PSMA-617: A prostate specific membrane antigen (PSMA) ligand for prostate cancer endotherapeutic applications
inferred← citeshttps://doi.org/10.1016/j.ejmech.2016.04.033openalex-snapshot
Design, synthesis and biological evaluation of PSMA/hepsin-targeted heterobivalent ligands
inferred← citeshttps://doi.org/10.1016/j.jphotochem.2024.115859openalex-snapshot
Development of a Flow Photocatalytic Reactor for the Photodecomposition of Ga(Iii) Complexes and Recovery of Free Ga(Iii) Radioisotopes
inferred← citeshttps://doi.org/10.1016/j.nucmedbio.2011.10.011openalex-snapshot
68Ga-labeling and in vivo evaluation of a uPAR binding DOTA- and NODAGA-conjugated peptide for PET imaging of invasive cancers
inferred← citeshttps://doi.org/10.1016/j.nucmedbio.2013.05.002openalex-snapshot
Kit-like 18F-labeling of RGD-19F-Arytrifluroborate in high yield and at extraordinarily high specific activity with preliminary in vivo tumor imaging
inferred← citeshttps://doi.org/10.1016/j.nucmedbio.2013.08.001openalex-snapshot
Single step 18F-labeling of dimeric cycloRGD for functional PET imaging of tumors in mice
inferred← citeshttps://doi.org/10.1016/j.nucmedbio.2015.06.003openalex-snapshot
A high-affinity [18F]-labeled phosphoramidate peptidomimetic PSMA-targeted inhibitor for PET imaging of prostate cancer
inferred← citeshttps://doi.org/10.1016/j.nucmedbio.2016.05.006openalex-snapshot
Preparation of [68Ga]PSMA-11 for PET–CT imaging using a manual synthesis module and organic matrix based 68Ge/68Ga generator
inferred← citeshttps://doi.org/10.1016/j.nucmedbio.2016.08.006openalex-snapshot
Radiolabeled enzyme inhibitors and binding agents targeting PSMA: Effective theranostic tools for imaging and therapy of prostate cancer
inferred← citeshttps://doi.org/10.1016/j.nucmedbio.2017.10.001openalex-snapshot
Assessment of PSMA targeting ligands bearing novel chelates with application to theranostics: Stability and complexation kinetics of 68 Ga 3+ , 111 In 3+ , 177 Lu 3+ and 225 Ac 3+
inferred← citeshttps://doi.org/10.1016/j.nucmedbio.2021.12.003openalex-snapshot
Radiolabeling of PSMA-617 with 89Zr: A novel use of DMSO to improve radiochemical yield and preliminary small-animal PET results
inferred← citeshttps://doi.org/10.1016/j.rpor.2014.04.016openalex-snapshot
68Ga-DOTA and analogs: Current status and future perspectives
inferred← citeshttps://doi.org/10.1016/j.snb.2017.04.179openalex-snapshot
A crab-like fluorescent probe for Ga(III) detection in body fluids and biological tissues
inferred← citeshttps://doi.org/10.1016/j.tetlet.2013.02.114openalex-snapshot
Development of a fast robust derivatization method of an extremely polar PET radiopharmaceutical: a critical aspect for starting a clinical trial
inferred← citeshttps://doi.org/10.1016/j.toxrep.2020.02.003openalex-snapshot
Evaluation of genotoxic potential of peptides used in nuclear medicine (PSMA -617 and -11, and ubiquicidine 29-41) using a flow-cytometric, semi-automated analysis of micronuclei frequency in cell cultures
inferred← citeshttps://doi.org/10.1016/j.ucl.2018.03.016openalex-snapshot
Advances in Urologic Imaging
inferred← citeshttps://doi.org/10.1016/j.urology.2015.12.048openalex-snapshot
The Role of Positron Emission Tomography With 68Gallium (Ga)-Labeled Prostate-specific Membrane Antigen (PSMA) in the Management of Patients With Organ-confined and Locally Advanced Prostate Cancer Prior to Radical Treatment and After Radical Prostatectomy
inferred← citeshttps://doi.org/10.1016/j.ymeth.2025.02.006openalex-snapshot
A free method for patient-specific 3D-VR anatomical modeling for presurgical planning using DICOM images and open-source software
inferred← citeshttps://doi.org/10.1021/acs.analchem.7b02016openalex-snapshot
Near-Infrared Neodymium Tag for Quantifying Targeted Biomarker and Counting Its Host Circulating Tumor Cells
inferred← citeshttps://doi.org/10.1021/acs.bioconjchem.0c00401openalex-snapshot
[68Ga]Ga-THP-Pam: A Bisphosphonate PET Tracer with Facile Radiolabeling and Broad Calcium Mineral Affinity
inferred← citeshttps://doi.org/10.1021/acs.bioconjchem.5b00679openalex-snapshot
Preclinical Comparative Study of 68Ga-Labeled DOTA, NOTA, and HBED-CC Chelated Radiotracers for Targeting PSMA
inferred← citeshttps://doi.org/10.1021/acs.bioconjchem.6b00195openalex-snapshot
[18F]Fluoroethyl Triazole Substituted PSMA Inhibitor Exhibiting Rapid Normal Organ Clearance
inferred← citeshttps://doi.org/10.1021/acs.bioconjchem.6b00222openalex-snapshot
Design of a Small-Molecule Drug Conjugate for Prostate Cancer Targeted Theranostics
inferred← citeshttps://doi.org/10.1021/acs.bioconjchem.7b00458openalex-snapshot
Improving the Imaging Contrast of 68Ga-PSMA-11 by Targeted Linker Design: Charged Spacer Moieties Enhance the Pharmacokinetic Properties
inferred← citeshttps://doi.org/10.1021/acs.jmedchem.0c01785openalex-snapshot
Development of Heterobivalent Theranostic Probes Having High Affinity/Selectivity for the GRPR/PSMA
inferred← citeshttps://doi.org/10.1021/acs.jmedchem.5b01210openalex-snapshot
Linker Modification Strategies To Control the Prostate-Specific Membrane Antigen (PSMA)-Targeting and Pharmacokinetic Properties of DOTA-Conjugated PSMA Inhibitors
inferred← citeshttps://doi.org/10.1021/acs.jmedchem.5b01268openalex-snapshot
[ 18 F]Fluorobenzoyllysinepentanedioic Acid Carbamates: New Scaffolds for Positron Emission Tomography (PET) Imaging of Prostate-Specific Membrane Antigen (PSMA)
inferred← citeshttps://doi.org/10.1021/acs.jmedchem.5b01850openalex-snapshot
Structure–Activity Relationship of 18F-Labeled Phosphoramidate Peptidomimetic Prostate-Specific Membrane Antigen (PSMA)-Targeted Inhibitor Analogues for PET Imaging of Prostate Cancer
inferred← citeshttps://doi.org/10.1021/acs.jmedchem.6c00960openalex-snapshot
Development and Advantages of O -(Carboxymethyl)- L -tyrosine-Based PSMA-Targeting Theranostics for Prostate Cancer
inferred← citeshttps://doi.org/10.1021/acs.jpcc.2c05415openalex-snapshot
Defined Coadsorption of Prostate Cancer Targeting Ligands and PEG on Gold Nanoparticles for Significantly Reduced Protein Adsorption in Cell Media
inferred← citeshttps://doi.org/10.1021/acs.molpharmaceut.7b00619openalex-snapshot
Synthesis and Assessment of Peptide Gd–DOTA Conjugates Targeting Extradomain B Fibronectin for Magnetic Resonance Molecular Imaging of Prostate Cancer
inferred← citeshttps://doi.org/10.1021/acs.molpharmaceut.9b01179openalex-snapshot
Development of 18F-Fluoroglycosylated PSMA-Ligands with Improved Renal Clearance Behavior
inferred← citeshttps://doi.org/10.1021/acsami.4c20602openalex-snapshot
Advances in Preclinical Research of Theranostic Radiopharmaceuticals in Nuclear Medicine
inferred← citeshttps://doi.org/10.1021/bc200279bopenalex-snapshot
68 Ga-Complex Lipophilicity and the Targeting Property of a Urea-Based PSMA Inhibitor for PET Imaging
inferred← citeshttps://doi.org/10.1021/bc3003919openalex-snapshot
Synthesis and Biological Evaluation of Low Molecular Weight Fluorescent Imaging Agents for the Prostate-Specific Membrane Antigen
inferred← citeshttps://doi.org/10.1021/jacs.1c07377openalex-snapshot
Magnetic Resonance Imaging of PSMA-Positive Prostate Cancer by a Targeted and Activatable Gd(III) MR Contrast Agent
inferred← citeshttps://doi.org/10.1021/jm200807mopenalex-snapshot
Novel Substrate-Based Inhibitors of Human Glutamate Carboxypeptidase II with Enhanced Lipophilicity
inferred← citeshttps://doi.org/10.1021/jm300710jopenalex-snapshot
Radiofluorinated Derivatives of 2-(Phosphonomethyl)pentanedioic Acid as Inhibitors of Prostate Specific Membrane Antigen (PSMA) for the Imaging of Prostate Cancer
inferred← citeshttps://doi.org/10.1021/jm400823wopenalex-snapshot
Effect of Chelators on the Pharmacokinetics of 99mTc-Labeled Imaging Agents for the Prostate-Specific Membrane Antigen (PSMA)
inferred← citeshttps://doi.org/10.1021/jm400895sopenalex-snapshot
Preparation of Asymmetric Urea Derivatives that Target Prostate-Specific Membrane Antigen for SPECT Imaging
inferred← citeshttps://doi.org/10.1021/jm401921jopenalex-snapshot
64Cu-Labeled Inhibitors of Prostate-Specific Membrane Antigen for PET Imaging of Prostate Cancer
inferred← citeshttps://doi.org/10.1021/mp4000844openalex-snapshot
A Multivalent Approach of Imaging Probe Design To Overcome an Endogenous Anion Binding Competition for Noninvasive Assessment of Prostate Specific Membrane Antigen
inferred← citeshttps://doi.org/10.1021/nn400669ropenalex-snapshot
Inherently Multimodal Nanoparticle-Driven Tracking and Real-Time Delineation of Orthotopic Prostate Tumors and Micrometastases
inferred← citeshttps://doi.org/10.1038/nrd4519openalex-snapshot
Principles in the design of ligand-targeted cancer therapeutics and imaging agents
inferred← citeshttps://doi.org/10.1038/pcan.2016.13openalex-snapshot
PET imaging of prostate-specific membrane antigen in prostate cancer: current state of the art and future challenges
inferred← citeshttps://doi.org/10.1038/s41573-020-0073-9openalex-snapshot
Radiopharmaceutical therapy in cancer: clinical advances and challenges
inferred← citeshttps://doi.org/10.1038/s41585-022-00670-6openalex-snapshot
Using PSMA imaging for prognostication in localized and advanced prostate cancer
inferred← citeshttps://doi.org/10.1038/s41598-020-59296-6openalex-snapshot
Role of Early PET/CT Imaging with 68Ga-PSMA in Staging and Restaging of Prostate Cancer
inferred← citeshttps://doi.org/10.1038/s41598-020-60099-yopenalex-snapshot
68Ga-labeled PSMA-11 (68Ga-isoPROtrace-11) synthesized with ready to use kit: normal biodistribution and uptake characteristics of tumour lesions
inferred← citeshttps://doi.org/10.1039/9781837677139-00278openalex-snapshot
Prostate-specific Membrane Antigen Targeted Prostate Imaging and Therapy
inferred← citeshttps://doi.org/10.1039/9781849733151-00062openalex-snapshot
Glutamate Carboxypeptidase II as a Therapeutic Target
inferred← citeshttps://doi.org/10.1039/c1ic90033aopenalex-snapshot
Macrocyclic coordination chemistry
inferred← citeshttps://doi.org/10.1039/c1md00117eopenalex-snapshot
Towards kit-like 18F-labeling of marimastat, a noncovalent inhibitor drug for in vivo PET imaging cancer associated matrix metalloproteases
inferred← citeshttps://doi.org/10.1039/d0nj04134copenalex-snapshot
Small molecule drug conjugates (SMDCs): an emerging strategy for anticancer drug design and discovery
inferred← citeshttps://doi.org/10.1053/j.seminoncol.2010.11.010openalex-snapshot
The Evolution of Imaging in Cancer: Current State and Future Challenges
inferred← citeshttps://doi.org/10.1053/j.semnuclmed.2012.04.004openalex-snapshot
Functional Imaging for Prostate Cancer: Therapeutic Implications
inferred← citeshttps://doi.org/10.1053/j.semnuclmed.2013.10.008openalex-snapshot
Molecular Imaging of Urogenital Diseases
inferred← citeshttps://doi.org/10.1053/j.semnuclmed.2023.06.007openalex-snapshot
Preclinical Development in Radiopharmaceutical Therapy for Prostate Cancer
inferred← citeshttps://doi.org/10.1055/a-1105-8039openalex-snapshot
[99mTc]Tc-PSMA-I&S: Anwendung zur Radioguided Surgery beim rezidivierten Prostatakarzinom
inferred← citeshttps://doi.org/10.1055/a-1759-1603openalex-snapshot
The Diagnostic Performance of 18F-PSMA-1007 PET/CT in Prostate Cancer Patients with Early Recurrence after Definitive Therapy with a PSA <10 ng/ml
inferred← citeshttps://doi.org/10.1080/07357907.2018.1430816openalex-snapshot
Radiolabeled mAbs as Molecular Imaging and/or Therapy Agents Targeting PSMA
inferred← citeshttps://doi.org/10.1080/19336918.2014.1000074openalex-snapshot
Tenascin-C: Exploitation and collateral damage in cancer management
inferred← citeshttps://doi.org/10.1089/cbr.2015.1964openalex-snapshot
64 Cu-PSMA-617 PET/CT Imaging of Prostate Adenocarcinoma: First In-Human Studies
inferred← citeshttps://doi.org/10.1089/cbr.2020.4686openalex-snapshot
Development of 68 Ga DOTA-CRH for PET/CT Imaging of ACTH-Dependent Cushing's Disease: Initial Study
inferred← citeshttps://doi.org/10.1089/cbr.2023.0024openalex-snapshot
Synthesis and Radiolabeling of Glu-Urea-Lys with 99m Tc-Tricarbonyl-Imidazole-Bathophenanthroline Disulfonate Chelation System and Biological Evaluation as Prostate-Specific Membrane Antigen Inhibitor
inferred← citeshttps://doi.org/10.1097/cad.0b013e32834a4554openalex-snapshot
Targeting of nanoparticles in cancer
inferred← citeshttps://doi.org/10.1097/mnm.0000000000001232openalex-snapshot
Enhancing capacity and synthesis of [68Ga]68-Ga-PSMA-HBED-CC with the lyophilized ready-to-use kit for nuclear pharmacy applications
inferred← citeshttps://doi.org/10.1097/rlu.0000000000002712openalex-snapshot
Incidental Finding of Acute Lymphocytic Leukemia in a Prostate-Specific Membrane Antigen PET/CT
inferred← citeshttps://doi.org/10.1109/iacs.2015.7103212openalex-snapshot
Hopfield Neural Network for the segmentation of Near Infrared Fluorescent images for diagnosing prostate cancer
inferred← citeshttps://doi.org/10.1109/iccvia.2015.7351905openalex-snapshot
Comparison between K mean and fuzzy C-mean methods for segmentation of near infrared fluorescent image for diagnosing prostate cancer
inferred← citeshttps://doi.org/10.1111/cbdd.13946openalex-snapshot
The utility of radiolabeled PSMA ligands for tumor imaging
inferred← citeshttps://doi.org/10.1111/febs.13557openalex-snapshot
Design of composite inhibitors targeting glutamate carboxypeptidase II : the importance of effector functionalities
inferred← citeshttps://doi.org/10.1146/annurev-med-062117-073027openalex-snapshot
Imaging of Prostate-Specific Membrane Antigen with Small-Molecule PET Radiotracers: From the Bench to Advanced Clinical Applications
inferred← citeshttps://doi.org/10.1155/2013/460546openalex-snapshot
Strategies for Imaging Androgen Receptor Signaling Pathway in Prostate Cancer: Implications for Hormonal Manipulation and Radiation Treatment
inferred← citeshttps://doi.org/10.1158/1078-0432.ccr-11-1357openalex-snapshot
2-(3-{1-Carboxy-5-[(6-[18F]Fluoro-Pyridine-3-Carbonyl)-Amino]-Pentyl}-Ureido)-Pentanedioic Acid, [18F]DCFPyL, a PSMA-Based PET Imaging Agent for Prostate Cancer
inferred← citeshttps://doi.org/10.1158/1535-7163.mct-14-0422openalex-snapshot
Development of Targeted Near-Infrared Imaging Agents for Prostate Cancer
inferred← citeshttps://doi.org/10.1177/1536012117737010openalex-snapshot
Radiochemistry and Preclinical PET Imaging of 68 Ga-Desferrioxamine Radiotracers Targeting Prostate-Specific Membrane Antigen
inferred← citeshttps://doi.org/10.1186/2191-219x-2-23openalex-snapshot
A dimerized urea-based inhibitor of the prostate-specific membrane antigen for 68Ga-PET imaging of prostate cancer
inferred← citeshttps://doi.org/10.1186/s12951-026-04639-0openalex-snapshot
Targeted 89Zr-Labeled metallofluorocarbon nanoemulsion for carcinoembryonic antigen PET
inferred← citeshttps://doi.org/10.1186/s13550-014-0063-1openalex-snapshot
Synthesis and preclinical evaluation of DOTAGA-conjugated PSMA ligands for functional imaging and endoradiotherapy of prostate cancer
inferred← citeshttps://doi.org/10.1186/s13550-015-0147-6openalex-snapshot
[111In]PSMA-I&T: expanding the spectrum of PSMA-I&T applications towards SPECT and radioguided surgery
inferred← citeshttps://doi.org/10.1186/s13550-017-0257-4openalex-snapshot
44Sc-PSMA-617 for radiotheragnostics in tandem with 177Lu-PSMA-617—preclinical investigations in comparison with 68Ga-PSMA-11 and 68Ga-PSMA-617
inferred← citeshttps://doi.org/10.1200/jco.23.02310openalex-snapshot
Resolute Progress Down a Long and Winding Road Leads to the Promised Land of Prostate-Specific Membrane Antigen–Based Therapies for Prostate Cancer
inferred← citeshttps://doi.org/10.1201/b15085-11openalex-snapshot
Emission Imaging
inferred← citeshttps://doi.org/10.1259/bjr.20180308openalex-snapshot
Theranostics of prostate cancer: from molecular imaging to precision molecular radiotherapy targeting the prostate specific membrane antigen
inferred← citeshttps://doi.org/10.1371/journal.pone.0068339openalex-snapshot
Evaluation of Phage Display Discovered Peptides as Ligands for Prostate-Specific Membrane Antigen (PSMA)
inferred← citeshttps://doi.org/10.1371/journal.pone.0145755openalex-snapshot
(R)-NODAGA-PSMA: A Versatile Precursor for Radiometal Labeling and Nuclear Imaging of PSMA-Positive Tumors
inferred← citeshttps://doi.org/10.1517/13543776.2013.789501openalex-snapshot
PSMA-targeted dendrimers: a patent evaluation (WO2012078534)
inferred← citeshttps://doi.org/10.15392/bjrs.v8i1.1115openalex-snapshot
O cenário mundial de radiofármacos emissores de pósitrons para diagnóstico e estadiamento de câncer de próstata em medicina nuclear
inferred← citeshttps://doi.org/10.1590/0100-3984.2024.0024openalex-snapshot
PSMA PET/CT in the Brazilian Unified Healthcare System reduces costs with futile salvage therapies in the management of cases of biochemical recurrence of prostate cancer
inferred← citeshttps://doi.org/10.17650/1726-9776-2021-17-4-136-150openalex-snapshot
Modern possibilities of application 99mTc-labeled prostate-specific membrane antigen ligands in prostate cancer
inferred← citeshttps://doi.org/10.18632/oncotarget.27239openalex-snapshot
The positivity rate of 68Gallium-PSMA-11 ligand PET/CT depends on the serum PSA-value in patients with biochemical recurrence of prostate cancer
inferred← citeshttps://doi.org/10.18632/oncotarget.415openalex-snapshot
A Modular Strategy to Prepare Multivalent Inhibitors of Prostate-Specific Membrane Antigen (PSMA)
inferred← citeshttps://doi.org/10.20450/mjcce.2014.131openalex-snapshot
Metallomics related to gallium compounds: biochemical and xenobiochemical aspects
inferred← citeshttps://doi.org/10.21037/tau.2019.07.20openalex-snapshot
Prostate specific membrane antigen (PSMA) imaging: the past is prologue
inferred← citeshttps://doi.org/10.2174/092986712799034888openalex-snapshot
Glutamate Carboxypeptidase II in Diagnosis and Treatment of Neurologic Disorders and Prostate Cancer
inferred← citeshttps://doi.org/10.2174/0929867327666201006153847openalex-snapshot
Evolution of Peptide-Based Prostate-Specific Membrane Antigen (PSMA) Inhibitors: An Approach to Novel Prostate Cancer Therapeutics
inferred← citeshttps://doi.org/10.2174/1568026611313080008openalex-snapshot
PET Imaging in Prostate Cancer: Focus on Prostate-Specific Membrane Antigen
inferred← citeshttps://doi.org/10.2174/1568026619666190201100739openalex-snapshot
Recent Advances in Prostate-Specific Membrane Antigen-Based Radiopharmaceuticals
inferred← citeshttps://doi.org/10.2174/1874471012666190515090755openalex-snapshot
68Ga/64Cu PSMA Bio-Distribution in Prostate Cancer Patients: Potential Pitfalls for Different Tracers
inferred← citeshttps://doi.org/10.2174/1874471012666190729151540openalex-snapshot
Toward the Discovery and Development of PSMA Targeted Inhibitors for Nuclear Medicine Applications
inferred← citeshttps://doi.org/10.2214/ajr.12.8816openalex-snapshot
Molecular Imaging of Prostate Cancer: PET Radiotracers
inferred← citeshttps://doi.org/10.2217/pme.11.35openalex-snapshot
Intersectional Innovation in Biomarker Development for Patient-Centric Medicine
inferred← citeshttps://doi.org/10.22465/kjuo.2022.20.4.207openalex-snapshot
An Update of Prostate-Specific Membrane Antigen Theranostics in Prostate Cancer
inferred← citeshttps://doi.org/10.2967/jnumed.110.083568openalex-snapshot
Optimization of Hapten-Peptide Labeling for Pretargeted ImmunoPET of Bispecific Antibody Using Generator-Produced 68Ga
inferred← citeshttps://doi.org/10.2967/jnumed.112.114512openalex-snapshot
Pharmacokinetic Properties of Peptidic Radiopharmaceuticals: Reduced Uptake of (EH)3-Conjugates in Important Organs
inferred← citeshttps://doi.org/10.2967/jnumed.114.147413openalex-snapshot
Preclinical Evaluation of a Tailor-Made DOTA-Conjugated PSMA Inhibitor with Optimized Linker Moiety for Imaging and Endoradiotherapy of Prostate Cancer
inferred← citeshttps://doi.org/10.2967/jnumed.114.149062openalex-snapshot
Preclinical Evaluation of 86Y-Labeled Inhibitors of Prostate-Specific Membrane Antigen for Dosimetry Estimates
inferred← citeshttps://doi.org/10.2967/jnumed.115.158550openalex-snapshot
68Ga- and 177Lu-Labeled PSMA I&T: Optimization of a PSMA-Targeted Theranostic Concept and First Proof-of-Concept Human Studies
inferred← citeshttps://doi.org/10.2967/jnumed.115.168443openalex-snapshot
177 Lu-Labeled Prostate-Specific Membrane Antigen Radioligand Therapy of Metastatic Castration-Resistant Prostate Cancer: Safety and Efficacy
inferred← citeshttps://doi.org/10.2967/jnumed.115.170720openalex-snapshot
The Rise of PSMA Ligands for Diagnosis and Therapy of Prostate Cancer
inferred← citeshttps://doi.org/10.2967/jnumed.118.212720openalex-snapshot
Synthesis and Preclinical Characterization of the PSMA-Targeted Hybrid Tracer PSMA-I&F for Nuclear and Fluorescence Imaging of Prostate Cancer
inferred← citeshttps://doi.org/10.2967/jnumed.119.229542openalex-snapshot
An 18F-Labeled PSMA Ligand for PET/CT of Prostate Cancer: First-in-Humans Observational Study and Clinical Experience with 18F-JK-PSMA-7 During the First Year of Application
inferred← citeshttps://doi.org/10.2967/jnumed.119.232330openalex-snapshot
Prostate-Specific Membrane Antigen–Guided Surgery
inferred← citeshttps://doi.org/10.2967/jnumed.121.262997openalex-snapshot
The History of Prostate-Specific Membrane Antigen as a Theranostic Target in Prostate Cancer: The Cornerstone Role of the Prostate Cancer Foundation
inferred← citeshttps://doi.org/10.33719/yud.2022;17-2-1035767openalex-snapshot
Is it time to stage prostate cancer using molecular imaging?
inferred← citeshttps://doi.org/10.33719/yud.2022;17-2-1068641openalex-snapshot
Active surveillance of prostate cancer with multiparametric magnetic resonance imaging: Review of the literature
inferred← citeshttps://doi.org/10.3389/fchem.2018.00107openalex-snapshot
Synthesis of Symmetrical Tetrameric Conjugates of the Radiolanthanide Chelator DOTPI for Application in Endoradiotherapy by Means of Click Chemistry
inferred← citeshttps://doi.org/10.3389/fchem.2022.995351openalex-snapshot
Urea-based anticancer agents. Exploring 100-years of research with an eye to the future
inferred← citeshttps://doi.org/10.3390/cancers11091371openalex-snapshot
Bispecific GRPR-Antagonistic Anti-PSMA/GRPR Heterodimer for PET and SPECT Diagnostic Imaging of Prostate Cancer
inferred← citeshttps://doi.org/10.3390/cancers12020398openalex-snapshot
PSA and PSA Kinetics Thresholds for the Presence of 68Ga-PSMA-11 PET/CT-Detectable Lesions in Patients with Biochemical Recurrent Prostate Cancer
inferred← citeshttps://doi.org/10.3390/cancers13163967openalex-snapshot
PSMA-Targeting Radiopharmaceuticals for Prostate Cancer Therapy: Recent Developments and Future Perspectives
inferred← citeshttps://doi.org/10.3390/cancers18182919openalex-snapshot
Impact of 18F-DCFPyL-PSMA PET/CT on Radiotherapy Planning and Treatment Intensification in Occult Biochemical Recurrence of Prostate Cancer After Radical Prostatectomy
inferred← citeshttps://doi.org/10.3390/diagnostics13010158openalex-snapshot
PSMA Receptor-Based PET-CT: The Basics and Current Status in Clinical and Research Applications
inferred← citeshttps://doi.org/10.3390/ijms27104642openalex-snapshot
A Review of Approaches to the Synthesis of DCL-Based Prostate-Specific Membrane Antigen Ligands
inferred← citeshttps://doi.org/10.3390/ijms27177785openalex-snapshot
[225Ac]Ac-iPSMA Radiopharmaceuticals for Targeted Alpha Therapy: Design, Synthesis, and Preclinical Evaluation
inferred← citeshttps://doi.org/10.3390/inorganics8010005openalex-snapshot
Synthesis and Evaluation of 99mTc-Tricabonyl Labeled Isonitrile Conjugates for Prostate-Specific Membrane Antigen (PSMA) Image
inferred← citeshttps://doi.org/10.3390/molecules200814860openalex-snapshot
Development of a Single Vial Kit Solution for Radiolabeling of 68Ga-DKFZ-PSMA-11 and Its Performance in Prostate Cancer Patients
inferred← citeshttps://doi.org/10.3390/molecules22040523openalex-snapshot
Metal-Based PSMA Radioligands
inferred← citeshttps://doi.org/10.3390/molecules28166158openalex-snapshot
Preclinical Evaluation of a New Series of Albumin-Binding 177Lu-Labeled PSMA-Based Low-Molecular-Weight Radiotherapeutics
inferred← citeshttps://doi.org/10.3390/molecules30102095openalex-snapshot
NOTA and NODAGA Radionuclide Complexing Agents: Versatile Approaches for Advancements in Radiochemistry
inferred← citeshttps://doi.org/10.3390/ph7070779openalex-snapshot
Novel Preclinical and Radiopharmaceutical Aspects of [68Ga]Ga-PSMA-HBED-CC: A New PET Tracer for Imaging of Prostate Cancer
inferred← citeshttps://doi.org/10.3390/pharmaceutics14102051openalex-snapshot
Glu-Urea-Lys Scaffold Functionalized Superparamagnetic Iron Oxide Nanoparticles Targeting PSMA for In Vivo Molecular MRI of Prostate Cancer
inferred← citeshttps://doi.org/10.37336/2707-0700-2020-3-3openalex-snapshot
99MTc-PSMA – radionuclide imaging of prostate cancer: an innovative diagnostic direction in nuclear medicine
inferred← citeshttps://doi.org/10.4103/wjnm.wjnm_82_18openalex-snapshot
Quality control and GMP synthesis of 68Ga-prostate-specific membrane antigen-11 for detection of low- and high-grade prostate cancer
inferred← citeshttps://doi.org/10.51847/avnjs4ouwdopenalex-snapshot
18F-DCFPyL PSMA PET/CT Enhances Detection of Occult Recurrence and Refines Management in Post-Prostatectomy Biochemical Failure
inferred← citeshttps://doi.org/10.5772/64016openalex-snapshot
Targeted Therapy for Metastatic Prostate Cancer with Radionuclides
inferred← citeshttps://doi.org/10.70675/ba007a31z10a7z43dez94faz4667fd54fdceopenalex-snapshot
Multifunctional platforms for cancer theranosis
showing the first 200 of 203 · page through all 203
Editorial review for independent work. ICSAC — the Institute for Complexity Science and Advanced Computing — runs a structured editorial panel for researchers publishing outside journals, and publishes on CiteStamp rails. Submission is free and goes through ORCID: icsacinstitute.org/submit.